Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Emerg Med Clin North Am ; 33(4): 753-64, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26493521

ABSTRACT

Present in all patient populations, altered mental status (AMS) is a common, but nonspecific emergency department (ED) presentation that can signify serious underlying pathology. Delirium is a more defined mental status change caused by another medical condition that carries a high morbidity and mortality if missed. However, ED physicians miss the condition in more than 50% of cases. The ED physician should maintain a high index of suspicion for delirium, because if missed in the ED, delirium is more likely to be missed on the floors as well. Management of delirium is directed toward treating the underlying course.


Subject(s)
Delirium/diagnosis , Delirium/therapy , Disease Management , Emergency Service, Hospital , Mental Status Schedule , Humans
2.
Hum Reprod ; 27(10): 2933-40, 2012 Oct.
Article in English | MEDLINE | ID: mdl-22888169

ABSTRACT

STUDY QUESTION: What is the effect of pravastatin on antiphospholipid antibody (aPL) modulation of human first trimester trophoblast function? SUMMARY ANSWER: Pravastatin does not prevent the effects of aPL on human first trimester trophoblast cell function. WHAT IS KNOWN ALREADY: Antiphospholipid syndrome (APS) is associated with recurrent pregnancy loss and late pregnancy complications, such as pre-eclampsia, owing to direct targeting of the placenta by aPL. While treatment with heparin reduces the rate of pregnancy loss, the risk for severe pre-eclampsia remains high. Thus, there is a need to find alternative treatments for the prenatal management of patients with APS. Statins have recently been shown to prevent aPL-mediated fetal loss in mice but their effects on a human pregnancy model of APS have not yet been studied. DESIGN, DATA COLLECTION, METHODS: The human first trimester trophoblast cell line, HTR8, and human first trimester trophoblast primary cultures were incubated with or without a mouse anti-human beta 2 glycoprotein I (ß(2)GPI) monoclonal antibody in the presence or absence of pravastatin. Cytokine and angiogenic factor secretion were measured by enzyme-linked immunosorbent assay and multiplex analysis. Cell migration was measured using a colorimetric two-chamber migration assay. MAIN FINDINGS: Using the human first trimester trophoblast cell line, HTR8, pravastatin significantly augmented, compared with no treatment, aPL-dependent secretion of interleukin (IL)-8 (P< 0.05), IL-1ß (P< 0.05) and soluble endoglin (P< 0.01) but had no effect on aPL-induced up-regulation of vascular endothelial growth factor, placenta growth factor or growth-related oncogene alpha secretion. Furthermore, pravastatin alone limited basal HTR8 cell migration (P< 0.01), and did not mitigate the adverse effect of aPL on trophoblast migration. Pravastatin also had no impact on the secretion of pro-inflammatory cytokines and angiogenic factors by primary human first trimester trophoblast cells exposed to aPL. LIMITATIONS AND WIDER IMPLICATIONS OF THE FINDINGS: While our in vitro findings suggest that pravastatin may not be effective in preventing pregnancy complications in patients with APS, the in vivo condition may be more complex, and thus, more studies are needed to determine the effectiveness of pravastatin in the prevention of aPL-associated pregnancy complications in humans. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the American Heart Association.


Subject(s)
Antiphospholipid Syndrome/immunology , Pravastatin/pharmacology , Trophoblasts/drug effects , Angiogenesis Inducing Agents/metabolism , Antibodies, Antiphospholipid/immunology , Antibodies, Monoclonal , Antiphospholipid Syndrome/drug therapy , Cell Line , Cell Movement/drug effects , Cytokines/metabolism , Enzyme-Linked Immunosorbent Assay , Humans , Multiplex Polymerase Chain Reaction , Trophoblasts/immunology , Trophoblasts/pathology , beta 2-Glycoprotein I/immunology
3.
Health Care Women Int ; 33(6): 560-74, 2012.
Article in English | MEDLINE | ID: mdl-22577742

ABSTRACT

The use of hormone replacement therapy (HRT) to alleviate menopausal symptoms is associated with risks of cardiovascular and thromboembolic diseases and breast cancer. In this qualitative study, we investigated how women in low-resource settings manage menopausal symptoms without HRT. We interviewed 34 menopausal Ghanaian women about their sources of information, perceptions, attitudes, and self-management methods for alleviating menopausal symptoms. The majority of the women used a combination of nonhormonal medications and complimentary and alternative medicine (CAM), including dietary modifications, exercise, and other lifestyle changes to effectively manage menopausal symptoms. Sources of information about menopause influenced participants' perceptions, attitudes, and self-management choices.


Subject(s)
Health Knowledge, Attitudes, Practice , Menopause/psychology , Perception , Aged , Complementary Therapies , Exercise , Female , Ghana , Hot Flashes , Humans , Information Seeking Behavior , Life Style , Middle Aged , Qualitative Research , Self Care , Socioeconomic Factors , Surveys and Questionnaires
SELECTION OF CITATIONS
SEARCH DETAIL
...